Função renal em pacientes com leishmaniose muco-cutânea tratados com antimoniais pentavalentes

Veiga, Joel Paulo Russomano; Rosa, Tânia Torres; Kimachi, Tatsuto; Wolff, E; Sampaio, Raimunda Nonata Ribeiro; Gagliardi, Antônio; Costa, Jackson Maurício Lopes; Marsden, Philip D.

doi:10.1590/s0036-46651985000600002

Cited by 17 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug is rapidly excreted by the kidneys [ 66 ] but cases of renal tubular dysfunction with damage to the concentration capability of kidneys [ 66 , 72 ], including acute renal failure [ 73 , 74 ], have also been reported. Glucantime treatment has raised the levels of blood creatinine [ 66 , 74 , 75 ] and urea nitrogen [ 73 ]. Additionally, a defect in urine concentration has been attributed to the antagonist effect of antimonials on neurohypophysis hormone [ 66 ].…”

Section: Discussionmentioning

confidence: 99%

Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis

et al. 2015

View full text Add to dashboard Cite

BackgroundImmucillins ImmA (IA), ImmH (IH) and SerMe-ImmH (SMIH) are synthetic deazapurine nucleoside analogues that inhibit Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis multiplication in vitro without macrophage toxicity. Immucillins are compared to the Glucantime standard drug in the chemotherapy of Leishmania (L.) infantum chagasi infection in mice and hamsters. These agents are tested for toxicity and immune system response.Methodology/Principal FindingsBALB/c mice were infected with 107 amastigotes, treated with IA, IH, SMIH or Glucantime (2.5mg/kg/day) and monitored for clinical variables, parasite load, antibody levels and splenocyte IFN-γ, TNF-α, and IL-10 expression. Cytokines and CD4+, CD8+ and CD19+ lymphocyte frequencies were assessed in uninfected controls and in response to immucillins. Urea, creatinine, GOT and GPT levels were monitored in sera. Anti-Leishmania-specific IgG1 antibodies (anti-NH36) increased in untreated animals. IgG2a response, high levels of IFN-γ, TNF-α and lower levels of IL-10 were detected in mice treated with the immucillins and Glucantime. Immucillins permitted normal weight gain, prevented hepato-splenomegaly and cleared the parasite infection (85–89%) without renal and hepatic toxicity. Immucillins promoted 35% lower secretion of IFN-γ in uninfected controls than in infected mice. IA and IH increased the CD4+ T and CD19+ B cell frequencies. SMIH increased only the proportion of CD-19 B cells. IA and IH also cured infected hamsters with lower toxicity than Glucantime.Conclusions/SignificanceImmucillins IA, IH and SMIH were effective in treating leishmaniasis in mice. In hamsters, IA and IH were also effective. The highest therapeutic efficacy was obtained with IA, possibly due to its induction of a TH1 immune response. Low immucillin doses were required and showed no toxicity. Our results disclose the potential use of IA and IH in the therapy of visceral leishmaniasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…For the past sixty years, pentavalent antimonials have been the leading treatment for CL cases. These drugs are known to cause liver, kidney, and cardiac toxicity, and other severe side effects (Veiga et al, 1985; Ribeiro et al, 1999). Treatment with pentavalent antimonials (Pentostam™ and Glucantime™), as well as other anti-leishmanial drugs, is usually via parenteral routes, often intravenously (Croft et al, 2006; Croft and Yardley, 2002).…”

Section: Introductionmentioning

confidence: 99%

Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana

et al. 2017

View full text Add to dashboard Cite

Leishmania mexicana infection causes localized skin lesions that can lead to tissue damage and permanent disfigurement if not resolved. Currently, recommended treatments include intravenous administration of Amphotericin B, which is undesirable due to the associated cost and patient burden related to receiving regular injections. In this study, we evaluated the effect of topical treatment with a nanoliposomal formulation of Amphotericin B that is penetrable to the skin (SinaAmphoLeish 0.4%) in mice infected with L. mexicana by using ulcerated (BALB/c) and non-ulcerated (129SVE) models. BALB/c mice received a 4 week treatment following ulcerated lesion development, while 129SVE mice received a 10 week treatment beginning at week 5 post-infection. Although mice from both models showed comparable susceptibility to L. mexicana infection after topical treatment with SinaAmphoLeish relative to controls, 129SVE mice displayed a transient decrease in lesion sizes which eventually became similar to control mice. On other hand this treatment resulted in no reduction in the lesion sizes in BALB/c mice. 129SVE treated mice exhibited greater IFN-γ, IL-4, and IL-10 cytokine levels and higher T-cell proliferation in re-stimulated draining lymph node cells. BALB/c mice showed no differences in cytokine responses between treated and control mice. These findings indicate that topical SinaAmphoLeish treatment is not likely to be effective in the treatment of cutaneous leishmaniasis caused by L. mexicana.

show abstract

Interventions for American cutaneous and mucocutaneous leishmaniasis

Pinart¹,

Rueda

Romero

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Função renal em pacientes com leishmaniose muco-cutânea tratados com antimoniais pentavalentes

Cited by 17 publications

References 6 publications

Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis

Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis

Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana

Interventions for American cutaneous and mucocutaneous leishmaniasis

Contact Info

Product

Resources

About